The management of lomustine overdose in malignant glioma patients
| Autor: | Antonella Palla, Christoph Renner, Ghazaleh Tabatabai, Isabel Tritschler, Michael Weller, Hans-Georg Wirsching |
|---|---|
| Přispěvatelé: | University of Zurich, Wirsching, Hans-Georg |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Vincristine business.industry medicine.medical_treatment Brain tumor Medicine (miscellaneous) 610 Medicine & health 2701 Medicine (miscellaneous) Articles Lomustine medicine.disease Procarbazine 10040 Clinic for Neurology Radiation therapy Internal medicine Glioma medicine Complication business Lomustine overdose medicine.drug |
| Zdroj: | Neuro-Oncology Practice. 1:178-183 |
| ISSN: | 2054-2585 2054-2577 |
| DOI: | 10.1093/nop/npu023 |
| Popis: | Lomustine is an oral alkylating drug commonly used for brain tumor patients. Recently, the lomustine-containing PCV polychemotherapy regime (procarbazine, CCNU/lomustine, and vincristine) in combination with radiotherapy has become the standard of care for anaplastic oligodendroglioma with 1p/19q codeletion and high-risk low-grade glioma. Here, we review the literature of all reported cases of lomustine overdose, highlight complications by exemplifying a case of inadvertent lomustine overdose, and outline the management of this potential complication of outpatient PCV therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|